Manulife Financial Corporation (0V5H.L)
| Previous close | 35.76 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,736 |
| Market cap | 69.53B |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | 0.08 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Manulife Launches a Two-Year Strategic Charity Partnership with Mind HK
Manulife Hong Kong today announced a two-year strategic partnership with Mind HK, a Hong Kong-based mental health charity, to raise public awareness of the importance of mental health and to influence the development of mental health support services in Hong Kong. This partnership will help advance one of Manulife's Impact Agenda commitments to empower sustained health and well-being. Over the course of the partnership, the two organizations will work together to organize a series of awareness e
- PR Newswire
Manulife Financial Corporation announces Dividend Rates on Non-cumulative Rate Reset Class 1 Shares Series 15 and Non-cumulative Floating Rate Class 1 Shares Series 16
Manulife Financial Corporation ("Manulife") today announced the applicable dividend rates for its Non-cumulative Rate Reset Class 1 Shares Series 15 (the "Series 15 Preferred Shares") (TSX: MFC.PR.L) and Non-cumulative Floating Rate Class 1 Shares Series 16 (the "Series 16 Preferred Shares").
- PR Newswire
Manulife/John Hancock Enters Five-Year, Multimillion Dollar Research Collaboration with MIT AgeLab to Drive Longevity Innovation and Research
John Hancock, along with its Toronto-based parent company Manulife (NYSE: MFC), today announced a five-year, multimillion-dollar research collaboration with the Massachusetts Institute of Technology (MIT) AgeLab, a multi-disciplinary research institute that works with business, government, and NGOs, leading innovation and research to help improve the quality of life for the aging population and their loved ones. Over the next five years, Manulife/John Hancock and the MIT AgeLab will collaborate
